Savva, Renos (2019) Targeting uracil-DNA glycosylases for therapeutic outcomes using insights from virus evolution. Future Medicinal Chemistry 11 (11), ISSN 1756-8919.
|
Text
FMC_UngTherapeutics-Review_AuthorAcceptedVersion.pdf - Author's Accepted Manuscript Download (4MB) | Preview |
Abstract
Ung-type uracil-DNA glycosylases are frontline defenders of DNA sequence fidelity in bacteria, plants, and animals; Ungs also directly assist both innate and humoral immunity. Critically important in viral pathogenesis, whether acting for or against viral DNA persistence, Ungs also have therapeutic relevance to cancer, microbial, and parasitic diseases. Ung catalytic specificity is uniquely conserved, yet selective antiviral drugging of the Ung catalytic pocket is tractable. However, more promising precision therapy approaches present themselves via insights from viral strategies, including sequestration or adaptation of Ung for non-canonical roles. A universal Ung inhibition mechanism, converged upon by unrelated viruses, could also inform design of compounds to inhibit specific distinct Ungs. Extrapolating current developments, the character of such novel chemical entities is proposed.
Metadata
| Item Type: | Article |
|---|---|
| Keyword(s) / Subject(s): | Uracil-DNA, Ung, uracil-DNA glycosylase, Ugi, p56, Vpr, uracil-DNA glycosylase inhibitor, herpesvirus, HIV, Human Immunodeficiency Virus type 1, poxvirus, tuberculosis, methicillin resistant Staphylococcus aureus, MRSA, structure-based drug design, SBDD |
| School: | Birkbeck Faculties and Schools > Faculty of Science > School of Natural Sciences |
| Research Centres and Institutes: | Innovation Management Research, Birkbeck Centre for |
| Depositing User: | Renos Savva |
| Date Deposited: | 01 May 2019 07:09 |
| Last Modified: | 02 Aug 2023 17:51 |
| URI: | https://eprints.bbk.ac.uk/id/eprint/27376 |
Statistics
Additional statistics are available via IRStats2.
Archive Staff Only (login required)
